PDGFRA mutant GIST has a stronger immune signature profile with an abundance of CD8+ and CD45+ cells, making it a more favorable molecular environment for cytolytic activity as compared to KIT mutant GIST [21]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.